Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 2 Colonic Neoplasms 2 Turcot syndrome 1 Recurrence 1 Rectal Neoplasms 1 Oropharyngeal Neoplasms 1 Mouth Neoplasms 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1 Head and Neck Neoplasms 1 Glioma 1 Carcinoma 1

Interventions

Cyclophosphamide 25 fludarabine 19 Dexamethasone 17 pembrolizumab 13 Rituximab 12 venetoclax 9 Lenalidomide 9 Gemcitabine 9 Etoposide 9 pomalidomide 8 Vincristine 7 glofitamab 6 fludarabine phosphate 6 carfilzomib 6 Temozolomide 6 obinutuzumab 5 daratumumab 5 Prednisone 5 Nivolumab 5 Doxorubicin 5 Cisplatin 5 Calcium Dobesilate 5 Bortezomib 5 zanubrutinib 4 selinexor 4 Immunotherapy, Adoptive 4 Cytarabine 4 Carboplatin 4 Azacitidine 4 ruxolitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Celecoxib × 90 days × Clear all

NCT02115074 2026-03-18

FLUVABREX

Centre Oscar Lambret

Phase 1 Completed

Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡